These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34577877)

  • 21. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary levels of disease-related biomarkers in the early stages of Parkinson's and Alzheimer's disease:
    Sabaei M; Rahimian S; Haj Mohamad Ebrahim Ketabforoush A; Rasoolijazi H; Zamani B; Hajiakhoundi F; Soleimani M; Shahidi G; Faramarzi M
    IBRO Neurosci Rep; 2023 Jun; 14():285-292. PubMed ID: 36942319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment.
    Korff A; Liu C; Ginghina C; Shi M; Zhang J;
    J Alzheimers Dis; 2013; 36(4):679-88. PubMed ID: 23603399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
    van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
    Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOE4 exacerbates α-synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology.
    Jin Y; Li F; Sonoustoun B; Kondru NC; Martens YA; Qiao W; Heckman MG; Ikezu TC; Li Z; Burgess JD; Amerna D; O'Leary J; DeTure MA; Zhao J; McLean PJ; Dickson DW; Ross OA; Bu G; Zhao N
    Acta Neuropathol; 2022 Jun; 143(6):641-662. PubMed ID: 35471463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of cerebrospinal fluid α-synuclein with total and phospho-tau
    Vergallo A; Bun RS; Toschi N; Baldacci F; Zetterberg H; Blennow K; Cavedo E; Lamari F; Habert MO; Dubois B; Floris R; Garaci F; Lista S; Hampel H; ;
    Alzheimers Dement; 2018 Dec; 14(12):1623-1631. PubMed ID: 30055132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Diagnostic Value of Red Blood Cells α-Synuclein Heteroaggregates in Alzheimer's Disease.
    Baldacci F; Daniele S; Piccarducci R; Giampietri L; Pietrobono D; Giorgi FS; Nicoletti V; Frosini D; Libertini P; Lo Gerfo A; Petrozzi L; Donadio E; Betti L; Trincavelli ML; Siciliano G; Ceravolo R; Tognoni G; Bonuccelli U; Martini C
    Mol Neurobiol; 2019 Sep; 56(9):6451-6459. PubMed ID: 30826968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.
    Mattsson N; Insel P; Tosun D; Zhang J; Jack CR; Galasko D; Weiner M;
    PLoS One; 2013; 8(12):e85443. PubMed ID: 24392009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia.
    Álvarez I; Diez-Fairen M; Aguilar M; González JM; Ysamat M; Tartari JP; Carcel M; Alonso A; Brix B; Arendt P; Pastor P
    Eur J Neurol; 2021 Apr; 28(4):1142-1152. PubMed ID: 33236496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.
    Babić Leko M; Borovečki F; Dejanović N; Hof PR; Šimić G
    J Alzheimers Dis; 2016; 50(3):765-78. PubMed ID: 26836160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid α-synuclein predicts neurodegeneration and clinical progression in non-demented elders.
    Li JQ; Bi YL; Shen XN; Wang HF; Xu W; Tan CC; Dong Q; Wang YJ; Tan L; Yu JT;
    Transl Neurodegener; 2020 Nov; 9(1):41. PubMed ID: 33228804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives.
    Baiardi S; Hansson O; Levin J; Parchi P
    Alzheimers Dement; 2024 Aug; 20(8):5757-5770. PubMed ID: 38955137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.
    Berge G; Sando SB; Albrektsen G; Lauridsen C; Møller I; Grøntvedt GR; Bråthen G; White LR
    BMC Neurol; 2016 Sep; 16(1):180. PubMed ID: 27653987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia.
    Diaz-Lucena D; Escaramis G; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Santana I; Del Rio JA; Martí E; Ferrer I; Baldeiras I; Zerr I; Llorens F
    J Neurol; 2020 Sep; 267(9):2567-2581. PubMed ID: 32372181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.